Shanghai Xinsu Medical Technology Co., Ltd. (hereinafter referred to as "ATANTARES（Chinese：芯宿科技") has completed the 100 million yuan Pre-A round and Pre-A + round of financing, on July 31, 2023.Organized by Asia Green Fund（Chinese：绿动资本）, Fosun Group's FOSUN HEALTH CAPITAL（Chinese：复健资本）, Alibaba Health（Chinese：阿里健康）and FREEFUND（Chinese：峰瑞资本）, QIMING VENTUR E PAR TNERS（Chinese：启明创投）and other old shareowners participated in the investment. This round of financing is mainly used for Product Research & Development and service operations and capacity expansion. It is understood that ATANTARES is about to start a new round of financing.
ATANTARES is a company that transforms medicine with smart chips . Committed to using semiconductor technology to empower biomedicine, using the inherent miniaturization and high integration characteristics of silicon chips and microfluidic technology to provide ultra-high throughput and ultra-high sensitivity to meet the needs of rapid development in fields such as medical health, synthetic biology and DNA storage.
ATANTARES took the lead in proposing and independently developed the first molecular chip in China, which opened the innovation trend of semiconductization of biotechnology driven by silicon-based chips in China. The first monetization application is DNA synthesis based on molecular chips, which is a typical interdisciplinary entrepreneurship. The current ATANTARES team has expanded to more than 60 people, of which the R & D team accounts for about 60%, covering more than ten disciplines such as integrated circuit design , MEMS, microfluidics , organic chemistry, molecular biology, and automation.
EqualOcean Network Data Discovery, in recent years, with the rapid development of Big data, Cloud Service, Internet of Things , and autonomous driving, the market demand has expanded year by year. It is expected that from 2023 to 2027, the market size of China's artificial intelligence chip will continue to rise. By 2024, the market size of China's artificial intelligence chip will exceed CNY 100 billion（ USD 1.549 billion ） ; by 2027, the market size of China's artificial intelligence chip will reach CNY 288.19 billion . The artificial intelligence chip industry is the core of the information industry, and its future development will be boundless. It is a key force leading a new round of scientific and technological revolution and industrial transformation.
In the future, ATANTARES will go overseas at a relatively low price to meet the needs of the US and other biotechnology markets ; Zhao Xinxin, founder of ATANTARES, believes that "high-throughput quantification of DBTL cycles in biotechnology research and development is a trend, and it also promotes DNA synthesis technology to high throughput." Zhao Xin analyzed that this trend has become more and more obvious in China in the past two or three years. "Taking AI + biopharmaceuticals as an example, more and more companies have begun to conduct wet experiments. AI , as a tool for characterizing high-dimensional space , has generated a large number of sequences that require high-throughput synthesis. Synthetic biology is also gradually establishing a high-throughput, automated system, which is also an opportunity for high-throughput DNA synthesis in China."
The leading companies of molecular chips at home and abroad are: Tongfang stock (Tongfang), Shenzhen BGI (BGI), Xilinx (Xilinx), etc. These companies have strong technical strength and market influence in the field of molecular chips, which promote the development and application of molecular chip technology.
The traditional column DNA synthesis has achieved the ultimate in the scenario where the number of primers required is small and the dosage is particularly large; however, traditional manufacturers still have room to improve in high-throughput DNA synthesis, which also gives DNA synthesis such as ATANTARES. New companies have market opportunities. In the future, with the breakthrough of DNA information storage technology and monetization, the demand and market potential of DNA synthesis will be further released.